Phase I Study of GX15-070 (NSC 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 02 May 2013
At a glance
- Drugs Obatoclax (Primary) ; Bortezomib
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Biomarker
- 02 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Nov 2012 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
- 14 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.